Leukemia News16.02.04 16:01 Age: 7 yrs
Ipsogen announces CE marking of its M-bcr FusionQuant™ assay. Category: Leukemia
 Marseille, France, February 16, 2004 - "Our M-bcr FusionQuant product is the first commercially available IVD assay in Europe for the quantification of the BCR-ABL gene, an acquired chromosomal abnormality occurring in about 90-95% of patients with Chronic Myeloid Leukaemia. The assay can now be utilised as a validated, standardised diagnostic tool in clinical centres in full compliance with the IVD Directive said Vincent Fert, President and CEO of IPSOGEN. “In addition this compliance represents significant improvement for leukaemia patients treated with Gleevec®, a small molecule antagonist of the tyrosine kinase activity of BCR-ABL. These patients can now benefit... IPSOGEN SAS (Marseille, FR) today announced that it has registered with AFSSAPS, the French regulatory health care body, the M-bcr FusionQuant™ product in compliance with the European Directive 98/79 regulating In Vitro Diagnostic Medical Devices.  |
|
